公开(公告)号：WO2022005098A1

公开(公告)日：2022-01-06

申请号：PCT/KR2021/007930

申请日：2021-06-24

申请人： 주식회사 인터파크바이오컨버전스 ,  포항공과대학교 산학협력단

发明人： 이하람 ,  장진아 ,  최유미 ,  황동규 ,  김명지

IPC分类号： C12N5/00 ,  C12N5/071 ,  C12N2533/90 ,  C12N5/0081 ,  C12N5/0688

摘要： 본 발명은 폐 오가노이드 배양용 조성물의 제조 방법, 그 조성물 및 이를 이용한 오가노이드 배양 방법에 관한 것으로, 본 발명은 기존의 매트리겔 기반 배양 시스템 대비하여 실제 조직 유사 환경을 조성할 수 있고, 특히 폐 오가노이드 배양에 있어서 조직 분화를 촉진시키고 실제 조직과 유사한 형태로 효과적으로 발달시키는 효과를 발휘한다.

公开(公告)号：WO2021260195A1

公开(公告)日：2021-12-30

申请号：PCT/EP2021/067543

申请日：2021-06-25

申请人： GENOME RESEARCH LIMITED

发明人： GARNETT, Mathew ,  PRICE, Stacey ,  FRANCIES, Hayley

IPC分类号： C12N5/00 ,  G01N33/50 ,  C12N15/113 ,  C12N2310/20 ,  C12N2510/00 ,  C12N2513/00 ,  C12N2533/52 ,  C12N2533/90 ,  C12N2539/00 ,  C12N5/0062 ,  G01N33/5014

摘要： The present invention provides methods, compositions and kits for use in the culture of organoids in solution. In particular, a method for producing an expanded population of organoids in vitro is provided. The method comprises providing a population of organoid progenitor cells or organoids and culturing the population of organoids in a composition comprising a culture medium and a scaffold matrix, wherein the scaffold matrix is present in the composition at a concentration that is equivalent to a concentration of between 2% (v/v) and 18% (v/v) of a complex protein hydrogel having a protein concentration between 12 and 18 mg/ml, thereby producing an expanded population of organoids. The invention is particularly useful in the context of high-throughput production of organoids such as e.g. for screening.

公开(公告)号：WO2021226207A2

公开(公告)日：2021-11-11

申请号：PCT/US2021/030840

申请日：2021-05-05

申请人： XYLYX BIO, INC.

发明人： O'NEILL, John ,  GERMANGUZ, Igal ,  ARANDA, Evelyn ,  XIONG, Jennifer ,  KISSEL, Natalia ,  NICHOLS, Alexandra ,  DALY, Drew

IPC分类号： C12N5/071 ,  C12N5/00 ,  C12N5/02 ,  C12N5/07 ,  C12N5/074 ,  C12N5/077 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2502/14 ,  C12N2502/27 ,  C12N2513/00 ,  C12N2533/90 ,  C12N5/0068 ,  C12N5/0693

摘要： A cell culture platform for modeling metastatic cancer is disclosed. The platform comprises one or more cell culture vessels comprising a plurality of compartments. Each compartment houses a substrate include a decellularized tissue-specific extracellular matrix derived from tissue of a different anatomical region. Each tissue-specific extracellular matrix comprises a homogenous mixture of macromolecule fragments including collagen, elastin, and glycosaminoglycan. A kit for culturing cells in biomimetic environments is also disclosed. The kit comprises a plurality of substrate precursors and at least one reagent. Each substrate precursor comprises a decellularized tissue-specific extracellular matrix derived from tissue of a different anatomical region. The tissue-specific extracellular matrix comprises a homogenous mixture of macromolecule fragments including collagen, elastin, and glycosaminoglycan. The reagent is configured to configured to convert each substrate precursor into a substrate adapted for culturing cells thereon. Methods of assessing a tumor-associated response of a cancer colony are also disclosed herein.

公开(公告)号：WO2022005106A1

公开(公告)日：2022-01-06

申请号：PCT/KR2021/007963

申请日：2021-06-24

申请人： 주식회사 인터파크바이오컨버전스 ,  포항공과대학교 산학협력단

发明人： 이하람 ,  장진아 ,  최유미 ,  황동규 ,  김명지

IPC分类号： C12N5/00 ,  C12N5/071 ,  C12N2533/90 ,  C12N5/0081 ,  C12N5/0676

摘要： 본 발명은 췌장 오가노이드 배양용 조성물의 제조 방법, 그 조성물 및 이를 이용한 오가노이드 배양 방법에 관한 것으로, 본 발명은 기존의 매트리겔 기반 배양 시스템 대비하여 실제 조직 유사 환경을 조성할 수 있고, 특히 췌장 오가노이드 배양에 있어서 조직 분화를 촉진시키고 실제 조직과 유사한 형태로 효과적으로 발달시키는 효과를 발휘한다.

公开(公告)号：WO2021262663A1

公开(公告)日：2021-12-30

申请号：PCT/US2021/038395

申请日：2021-06-22

申请人： LIFE TECHNOLOGIES CORPORATION

发明人： NEWMAN, Rhonda ,  AKENHEAD, Michael

IPC分类号： C12N5/0735 ,  C12N5/074 ,  C12N2500/25 ,  C12N2500/38 ,  C12N2500/99 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/235 ,  C12N2501/33 ,  C12N2501/727 ,  C12N2501/998 ,  C12N2513/00 ,  C12N2533/90 ,  C12N5/0606 ,  C12N5/0696

摘要： Described herein are cell culture media and/or cell culture media supplements that comprise at least one GSK3 inhibitor, a ROCK inhibitor, and one or more mitogenic growth factors, and methods of culturing and/or expanding pluripotent stem cells in 3D culture formats in the compositions described herein.

公开(公告)号：WO2022079272A1

公开(公告)日：2022-04-21

申请号：PCT/EP2021/078668

申请日：2021-10-15

申请人： KATHOLIEKE UNIVERSITEIT LEUVEN ,  TAMPERE UNIVERSITY FOUNDATION SR

发明人： KIAMEHR, Mostafa ,  VERFAILLIE, Catherine

IPC分类号： C12N5/00 ,  C12N5/077 ,  C12N5/071 ,  C12N2533/90 ,  C12N5/0012 ,  C12N5/0068 ,  C12N5/0657 ,  C12N5/0671

摘要： The invention relates to self-assembled peptide hydrogel spheroids, with a diameter of between 500 and 2500 µm, comprising cells encapsulated within said hydrogel. The invention further relates to in vitro methods of producing a hydrogel spheroid comprising cells, the method comprising: a) mixing a suspension of cells with a self-assembling peptide, and b) transferring an aliquot of the mixture obtained in step a) into an aqueous salt solution by applying a droplet of the mixture to the surface of the solution thereby forming a hydrogel spheroid comprising encapsulated cells, wherein the droplet has a volume of between 0,1 and 20 µl. and wherein the droplet comprises cells at a concentration of between 1 x 105 to 5 x 107 cells per ml solution.

公开(公告)号：WO2021141762A1

公开(公告)日：2021-07-15

申请号：PCT/US2020/066209

申请日：2020-12-18

申请人： BIOMILQ, INC.

发明人： STRICKLAND, Leila

IPC分类号： C12N5/00 ,  A61K38/17 ,  A23C9/12 ,  C12N2500/02 ,  C12N2513/00 ,  C12N2523/00 ,  C12N2533/00 ,  C12N2533/52 ,  C12N2533/54 ,  C12N2533/70 ,  C12N2533/72 ,  C12N2533/74 ,  C12N2533/90 ,  C12N5/0631

摘要： This invention relates to live cell constructs for in vitro and/or ex vivo production of cultured milk products from mammary cells, methods of producing isolated cultured milk products from mammary cells, bioreactors for producing isolated cultured milk products, and cultured milk products.

公开(公告)号：WO2020227835A1

公开(公告)日：2020-11-19

申请号：PCT/CA2020/050655

申请日：2020-05-14

申请人： SPIDERWORT INC. ,  UNIVERSITY OF OTTAWA

发明人： HICKEY, Ryan ,  PELLING, Andrew E. ,  CAMPUZANO, Santiago ,  DE SOUSA FARIA TISCHER, Paula Cristina ,  SZERESZEWSKI, Kama

IPC分类号： C12N5/04 ,  A23L29/00 ,  A23L33/00 ,  A61K47/38 ,  A61K47/46 ,  A61K9/10 ,  A61L27/50 ,  A61L27/52 ,  A61L27/54 ,  B01D11/02 ,  B33Y80/00 ,  C08J3/075 ,  C08J3/24 ,  C08J5/12 ,  C08L1/02 ,  C09J5/00 ,  C12N1/14 ,  C12N5/00 ,  C12N5/07 ,  C12N5/077 ,  A23L13/00 ,  A23L17/00 ,  A23L15/00 ,  A23L19/09 ,  A23L29/20 ,  A23L31/00 ,  A61L27/34 ,  A61L27/3637 ,  A61L27/3683 ,  A61L27/3826 ,  A61L27/48 ,  B01D11/0257 ,  B01D11/0288 ,  C08J2301/02 ,  C09D105/04 ,  C09D105/08 ,  C09D105/12 ,  C09D189/06 ,  C12N2533/54 ,  C12N2533/78 ,  C12N2533/90 ,  C12N2537/10 ,  C12N5/0062

摘要： Provided herein are composite scaffold biomaterials including two or more scaffold biomaterial subunits, each including a decellularized plant or fungal tissue from which cellular materials and nucleic acids of the tissue are removed, the decellularized plant or fungal tissue having a 3-dimensional porous structure, the two or more scaffold biomaterial subunits being assembled into the composite scaffold biomaterial and held together via gel casting using a hydrogel glue; via complementary interlocking geometry of the two or more scaffold biomaterial subunits; via guided assembly based biolithography (GAB); via chemical cross-linking; or any combinations thereof. Methods for producing such scaffold biomaterials, as well as methods and uses thereof, are also provided.

公开(公告)号：WO2022272042A2

公开(公告)日：2022-12-29

申请号：PCT/US2022/034869

申请日：2022-06-24

申请人： THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： MCDEVITT, Todd C. ,  VASIC, Ivana

IPC分类号： A61K35/545 ,  A61K38/18 ,  A61K35/28 ,  C07K14/51 ,  C12N15/00 ,  A61K35/12 ,  C12N15/113 ,  C12N2501/155 ,  C12N2501/727 ,  C12N2506/45 ,  C12N2510/00 ,  C12N2533/90 ,  C12N5/0611

摘要： Described herein are compositions, systems, and methods for obtaining primordial germ cells (PGCs) from pluripotent stem cells (PSCs). Inhibiting or bypassing tight junction formation in a population of pluripotent stem cells to generate a modified cell population, and contacting the modified cell population with BMP. Where inhibiting or bypassing tight junction formation includes incubating the population of pluripotent stem cells.

公开(公告)号：WO2022261471A2

公开(公告)日：2022-12-15

申请号：PCT/US2022/033066

申请日：2022-06-10

申请人： CHILDREN’S HOSPITAL MEDICAL CENTER

发明人： TAKEBE, Takanori ,  REZA, Hasan, Al

IPC分类号： C12N5/071 ,  C12N2500/38 ,  C12N2501/115 ,  C12N2501/119 ,  C12N2501/12 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/165 ,  C12N2501/2306 ,  C12N2501/385 ,  C12N2501/39 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/45 ,  C12N2533/52 ,  C12N2533/90 ,  C12N5/0671 ,  G01N33/48

摘要： Disclosed herein are improved methods of maturing pluripotent stem cell-derived liver organoids with the use of hemoglobin metabolites such as bilirubin. Furthermore, by modulating the amounts of bilirubin used, liver organoids can be used as a model for hyperbilirubinemia. The scalability and tractability of these liver organoids made them excellent targets for drug screening against diseases such as hyperbilirubinemia. Also shown herein is the use of exogenous L-gulonolactone oxidase for improving viability of bilirubin-treated liver organoids.